Novel Treatment Options in Head and Neck Cancer

被引：8
作者：
Schuler, Patrick J. [1 ]
Laban, Simon [1 ]
Doescher, Johannes [1 ]
Bullinger, Lars [2 ]
Hoffmann, Thomas K. [1 ]
机构：
[1] Ulm Univ, Med Ctr, Dept Otorhinolaryngol Head & Neck Surg, Frauensteige 12, D-89075 Ulm, Germany
[2] Ulm Univ, Med Ctr, Dept Internal Med 3, Ulm, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2017年 / 40卷 / 06期
关键词：
HNSCC; Immunotherapy; PD-1; Immune escape; Vaccination; SQUAMOUS-CELL CARCINOMA; OPEN-LABEL; RECURRENT; TRIAL; IMMUNOTHERAPY; MULTICENTER; COMBINATION; VACCINATION; MECHANISM; NIVOLUMAB;
D O I：
10.1159/000477254
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
The treatment of head and neck squamous cell carcinoma (HNSCC) has been a medical challenge with limited improvement in overall survival over the past few decades. However, recently, very interesting innovations in the field of immunotherapy have been shown to be beneficial for patients with advanced HNSCC. In this article, the latest medical developments are reviewed with special focus on the clinical achievements and current clinical studies in the field of immunotherapy. The landscape of clinical studies has changed considerably from antibody-based growth factor inhibition towards immune checkpoint modulation, and new indications in the adjuvant and neoadjuvant setting are being tested in large patient cohorts. Even the combination of 2 or more immune modulatory approaches and the correct synchronization with standard cancer therapy is promising and warrants suitable clinical trials. (C) 2017 S. Karger GmbH, Freiburg
引用
收藏
页码：342 / 346
页数：5
相关论文
共 35 条
  • [1] Signatures of mutational processes in human cancer
    Alexandrov, Ludmil B.
    Nik-Zainal, Serena
    Wedge, David C.
    Aparicio, Samuel A. J. R.
    Behjati, Sam
    Biankin, Andrew V.
    Bignell, Graham R.
    Bolli, Niccolo
    Borg, Ake
    Borresen-Dale, Anne-Lise
    Boyault, Sandrine
    Burkhardt, Birgit
    Butler, Adam P.
    Caldas, Carlos
    Davies, Helen R.
    Desmedt, Christine
    Eils, Roland
    Eyfjord, Jorunn Erla
    Foekens, John A.
    Greaves, Mel
    Hosoda, Fumie
    Hutter, Barbara
    Ilicic, Tomislav
    Imbeaud, Sandrine
    Imielinsk, Marcin
    Jaeger, Natalie
    Jones, David T. W.
    Jones, David
    Knappskog, Stian
    Kool, Marcel
    Lakhani, Sunil R.
    Lopez-Otin, Carlos
    Martin, Sancha
    Munshi, Nikhil C.
    Nakamura, Hiromi
    Northcott, Paul A.
    Pajic, Marina
    Papaemmanuil, Elli
    Paradiso, Angelo
    Pearson, John V.
    Puente, Xose S.
    Raine, Keiran
    Ramakrishna, Manasa
    Richardson, Andrea L.
    Richter, Julia
    Rosenstiel, Philip
    Schlesner, Matthias
    Schumacher, Ton N.
    Span, Paul N.
    Teague, Jon W.
    [J]. NATURE, 2013, 500 (7463) : 415 - +
  • [2] Phase Ib study of MEDI4736, a programmed cell death ligand-1 (PD-L1) antibody, in combination with tremelimumab, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, in patients (pts) with advanced NSCLC.
    Antonia, Scott Joseph
    Goldberg, Sarah B.
    Balmanoukian, Ani Sarkis
    Sanborn, Rachel E.
    Steele, Keith
    Narwal, Rajesh
    Robbins, Paul B.
    Gu, Yu
    Karakunnel, Joyson Joseph
    Rizvi, Naiyer A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [3] Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival
    Bonner, James A.
    Harari, Paul M.
    Giralt, Jordi
    Cohen, Roger B.
    Jones, Christopher U.
    Sur, Ranjan K.
    Raben, David
    Baselga, Jose
    Spencer, Sharon A.
    Zhu, Junming
    Youssoufian, Hagop
    Rowinsky, Eric K.
    Ang, K. Kian
    [J]. LANCET ONCOLOGY, 2010, 11 (01) : 21 - 28
  • [4] Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN
    Chow, Laura Q. M.
    Morishima, Chihiro
    Eaton, Keith D.
    Baik, Christina S.
    Goulart, Bernardo H.
    Anderson, Leslie N.
    Manjarrez, Kristi L.
    Dietsch, Gregory N.
    Bryan, James Kyle
    Hershberg, Robert M.
    Disis, Mary L.
    Martins, Renato G.
    [J]. CLINICAL CANCER RESEARCH, 2017, 23 (10) : 2442 - 2450
  • [5] Clinical targeting of the TNF and TNFR superfamilies
    Croft, Michael
    Benedict, Chris A.
    Ware, Carl E.
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2013, 12 (02) : 147 - 168
  • [6] Gene expression analyses and their possible clinical benefit in head and neck cancer
    Dietz, A.
    Loeffler, M.
    Rosolowski, M.
    Kreuz, M.
    Lordick, F.
    Knoedler, M.
    Mozet, C.
    Wichmann, G.
    [J]. HNO, 2015, 63 (11) : 773 - 785
  • [7] Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
    Ferris, R. L.
    Blumenschein, G., Jr.
    Fayette, J.
    Guigay, J.
    Colevas, A. D.
    Licitra, L.
    Harrington, K.
    Kasper, S.
    Vokes, E. E.
    Even, C.
    Worden, F.
    Saba, N. F.
    Iglesias Docampo, L. C.
    Haddad, R.
    Rordorf, T.
    Kiyota, N.
    Tahara, M.
    Monga, M.
    Lynch, M.
    Geese, W. J.
    Kopit, J.
    Shaw, J. W.
    Gillison, M. L.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2016, 375 (19) : 1856 - 1867
  • [8] A Phase 1 Safety Study of an IRX-2 Regimen in Patients With Squamous Cell Carcinoma of the Head and Neck
    Freeman, Scott M.
    Barrera Franco, Jose Luis
    Kenady, Daniel E.
    Baltzer, Lorraine
    Roth, Zygmund
    Brandwein, Harvey J.
    Hadden, John W.
    [J]. AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2011, 34 (02): : 173 - 178
  • [9] HGF/Met Signaling in Head and Neck Cancer: Impact on the Tumor Microenvironment
    Hartmann, Stefan
    Bhola, Neil E.
    Grandis, Jennifer R.
    [J]. CLINICAL CANCER RESEARCH, 2016, 22 (16) : 4005 - 4013
  • [10] Antigen-specific immunotherapy in head and neck cancer
    Hoffmann, Thomas K.
    Schuler, Patrick J.
    [J]. ADVANCES IN CELLULAR AND MOLECULAR OTOLARYNGOLOGY, 2013, 1 (01)
1234